Introduction Ophiuchus Technologies AG is a Swiss company specializing in regenerative medicine. It was established in 2013 as a spin-off company of the NOVAGENESIS FOUNDATION. The company is focused on producing and distributing a groundbreaking cell therapy called DrSC™ Neural, which utilizes proprietary regenerative stem cell technology. This technology has been developed over a decade through research and development in the United States and Canada. Ophiuchus Technologies aims to address a significant population of patients who currently have limited treatment options. The product, DrSC™ Neural, is designed to treat individuals with sub-acute and chronic spinal cord injury, traumatic brain injury, primary progressive MS (PPMS), and ALS/motor neurone disease. |